Correspondence: Inaccurate reference leads to tripling of reported FND prevalence

Highlights:

  • Perez et al asserted that FND is the “2nd most common” diagnosis in outpatient neurology.
  • Stone et al (2010), cited by Perez et al, does not support the “2nd most common” claim.
  • In Stone et al, a broad “functional/psychological” category was the second most common
  • FND is not synonymous with the “functional/psychological” category in Stone et al.

To the editor:

An article in NeuroImage: Clinical“Neuroimaging in functional neurological disorder: state of the field and research agenda” (Perez et al., 2021), cited a prominent paper (Stone et al., 2010) as evidence for the assertion that functional neurological disorder (FND) is the “2nd most common outpatient neurologic diagnosis.” Although studies have yielded varying FND prevalence rates, the claim that it is the second-most common diagnosis at outpatient neurology clinics represents an erroneous interpretation of the findings of the referenced 2010 paper.

FND is the current name for what was formerly called conversion disorder, the diagnosis previously given to patients believed to have psychogenic motor and gait dysfunctions, sensory deficits, and non-epileptic seizures. According to the 2013 edition of the Diagnostic and Statistical Manual of Mental Disorders and as noted in Perez et al, FND is not a diagnosis of exclusion but requires the presence of specific “rule-in” clinical signs believed to be incompatible with known neurological disease. Some of these clinical signs have long been used by neurologists and other clinicians to help them identify cases of conversion disorder.

Stone et al.,’s (2010) paper was one of several arising from the Scottish Neurological Symptoms Study (SNSS). The study reviewed records from multiple outpatient neurology clinics and reported that 209 of 3781 attendees, or less than 6 %, received diagnoses compatible with conversion disorder–in other words, what would now be called FND. In terms of ranking, this group of patients—labeled in the SNSS as having “functional” symptoms or diagnoses–was far down the list. The study found higher rates of many other conditions, including headache (19 %), epilepsy (14 %), peripheral nerve disorders (11 %), miscellaneous neurological disorders (10 %), multiple sclerosis/demyelination (7 %), spinal disorders (6 %) and Parkinson’s disease/movement disorders (6 %).

Earlier this year, a paper in the European Journal of Neurology (Mason et al., 2023) cited a different SNSS paper (Stone et al., 2009) to support the assertion that FND prevalence at outpatient neurology clinics was 5.4 %—far lower than the percentage needed to be the “2nd most common” diagnosis. Moreover, the authors of another paper (Foley et al., 2022) have recently issued a correction for the same misstatement of FND prevalence from the SNSS findings as the one identified in Perez et al.

The assertion that the SNSS found FND to be the “2nd most common” diagnosis at outpatient neurology clinics is based on a parallel and commonly repeated claim that the study found the prevalence in these settings to be 16 % (e.g. Ludwig et al., 2018). That rate is almost three times the 5.4 % prevalence recently highlighted in Mason et al. The extra patients included in this greatly expanded FND category were another 10 % collectively identified in the SNSS as having “psychological” symptoms or diagnoses. These “psychological” patients fell into a range of clinical sub-categories, among them hyperventilation, anxiety and depression, atypical facial/temporomandibular joint pain, post-head injury symptoms, fibromyalgia, repetitive strain injury, and alcohol excess. The SNSS paper cited in Perez et al reported that a combined grouping of the patients with “functional and psychological” symptoms or diagnoses had a prevalence of 16 % but did not provide any evidence that the 10 % included under the “psychological” label met, or could have met, the explicit FND requirement for rule-in clinical signs.

FND is not synonymous with the broader “functional and psychological” category in the SNSS and should not be presented as if it were. The post-hoc reinterpretation of previously reported data in a way that conflates FND with other complex conditions—almost tripling its apparent prevalence in the process–is an example of the phenomenon known as diagnostic creep. In any event, the SNSS results are a matter of record. Whatever future studies might determine about FND rates, the published findings cited by Perez et al and addressed in this letter do not support either the claim that it is the “2nd most common” diagnosis in outpatient neurology clinics or the related claim that its prevalence at these venues is 16 %.

Sincerely–

David Tuller (corresponding author)

Center for Global Public Health

School of Public Health

University of California, Berkeley

Berkeley, CA, USA

David Davies-Payne

Department of Radiology

Starship Children’s Hospital

Auckland, New Zealand

Jonathan Edwards

Department of Medicine

University College London

London, England, UK

Keith Geraghty

Centre for Primary Care and Health Services Research

Faculty of Biology, Medicine and Health

University of Manchester

Manchester, England, UK

Calliope Hollingue

Center for Autism and Related Disorders/Kennedy Krieger Institute

Department of Mental Health/Johns Hopkins Bloomberg School of Public Health

Johns Hopkins University

Baltimore, MD, USA

Mady Hornig

Department of Epidemiology

Columbia University Mailman School of Public Health

New York, NY, USA

Brian Hughes

School of Psychology

University of Galway

Galway, Ireland

Asad Khan

North West Lung Centre

Manchester University Hospitals

Manchester, England, UK

David Putrino

Department of Rehabilitation Medicine

Icahn School of Medicine at Mt Sinai

New York, NY, USA

John Swartzberg

Division of Infectious Diseases and Vaccinology

School of Public Health

University of California, Berkeley

Berkeley, CA, USA

Source: Correspondence: Inaccurate reference leads to tripling of reported FND prevalence. Neuroimage Clin. 2024 Feb 7;41:103537. doi: 10.1016/j.nicl.2023.103537. Epub ahead of print. PMID: 38330816. https://www.sciencedirect.com/science/article/pii/S2213158223002280 (Full text)

Graded exercise therapy and cognitive behavior therapy do not improve employment outcomes in ME/CFS

1 Introduction:

In a 1989 article, Wessely et al. [1] proposed a model of the onset and perpetuation of chronic fatigue syndrome, the illness often called myalgic encephalomyelitis and now frequently referred to as ME/CFS. In this model, patients’ symptoms were attributed to the effects of deconditioning following an acute illness. The symptoms were said to be perpetuated by patients’ persistent but purportedly unwarranted conviction that they continued to suffer from a medical disease that was exacerbated by exertion. The proposed treatment strategy combined gradual increases in activity to reverse the presumed deconditioning with efforts to alter patients’ supposedly misguided perceptions about their ailment.

ME/CFS has long been associated with marked disability and long-term sickness absences [2], with estimated rates of unemployment among patients ranging from 35% to 69% [3]. From the start, the promotion of behavioral and psychological rehabilitation has been intertwined with questions about whether ME/CFS patients with limited capacity to work should be able to receive some form of income or disability support. In a section on “sickness benefits” in the 1989 paper [1], the authors argued that decisions about social welfare payments should be linked to patients’ willingness to undergo behavioral and psychological interventions. “It is reasonable to expect a patient to cooperate with treatment before being labelled as chronically disabled,” noted the authors, notwithstanding the theoretical and unproven status of their model.

This rehabilitative approach achieved dominance over the next couple of decades, not only in the UK but in the US and many other countries. Graded exercise therapy (GET) and an illness-specific form of cognitive behavior therapy (CBT) became the predominant and most heavily researched ME/CFS interventions and were enshrined in multiple clinical guidelines. A 2005 review of the natural history of the illness [4], which found that only 5% of patients fully recovered spontaneously, noted “increasing evidence” for GET and CBT and therefore advised that “medical retirement should be postponed until a trial of such treatment has been given.”

While many studies have included employment status as a demographic data point [2, 3], fewer have specifically examined the relationship between GET and CBT and employment-related outcomes. Nonetheless, the results from the latter group are consistent and clear: The interventions do not lead to improved outcomes in employment status [5–13].

This question has taken on renewed urgency given the overlaps between ME/CFS and the phenomenon known as long Covid, or more formally as post-acute sequelae of SARS CoV-2 (PASC). A significant proportion of patients with prolonged symptoms after a coronavirus infection appear to suffer from the same cluster of symptoms that characterize ME/CFS, including pronounced exhaustion, relapses after minimal exertion known as post-exertional malaise (PEM), cognitive impairments, and orthostatic intolerance, among others. Like ME/CFS patients, many of this new PASC cohort have found that they are unable to sustain their previous level of employment. While the similarities between the two conditions have been widely noted by clinicians and medical investigators, they have also led to efforts to promote the traditional ME/CFS rehabilitation paradigm for this large wave of post-viral patients.

2 Employment outcomes in the PACE trial

After gaining momentum during the 1990 s and 2000 s, the GET/CBT approach was significantly reinforced with the 2011 publication in the Lancet of the first results of the PACE trial, the largest study of the two interventions for ME/CFS [5]. Additional PACE results were published in 2012 and 2013 [6, 7]. The study was partially funded by the UK’s Department for Work and Pensions (DWP). Officials at the agency presumably believed or hoped that the trial would provide robust data to support the use of these two strategies.

The PACE investigators presumably hoped for that as well; key members of the team maintained strong links with disability insurance companies, advising them that GET and CBT were effective in helping this group of challenging patients recover. In a 2002 essay for a UNUMProvident report on trends in disability [14], Michael Sharpe, a lead PACE investigator, wrote that “symptoms and disability” in patients with unexplained conditions “are shaped by psychological factors,” and in particular by “patients’ beliefs and fears.” He suggested that the promotion of biological disease models by ME/CFS patient advocates could impact health outcomes among insurance claimants.

Commenting on how public messaging and related “social factors” influenced the course of illness for these patients, Sharpe wrote: “Relevant factors include the information patients receive about the symptoms and how to cope with them. This information may be helpful or may stress the chronicity of the illness and promote helplessness. Such unhelpful information is found in “self-help” (!) books and increasingly on the Internet (see for example www.meassociation.org.uk)…Other social factors that perpetuate illness are anger with the person or organisation the illness is attributed to, or toward the insurer for not believing them.” In the article, Sharpe further argued that receiving financial benefits ultimately discouraged such claimants from getting better.

However, the data from PACE did not provide evidence that GET and CBT were effective in helping ME/CFS patients in the employment domain [6]. With 641 participants, PACE was the largest treatment trial for ME/CFS [5]. The investigators themselves referred to it as the “definitive” test of the two interventions [15]. In touting it as a success, they reported that around 60% had improved and 22% had recovered after treatment with GET and CBT, much more than in the other groups [5, 7]. However, these positive findings were all from subjective, self-reported measures. When such measures are paired with unblinded treatments, as in the PACE trial, they are subject to an unknown amount of bias.

PACE also included an employment measure as one of four objective outcomes, along with whether or not the participant was receiving social welfare or disability benefits, a step-test to assess fitness, and a six-minute-walking test. The results were uniformly poor. The first three measures produced null findings across the board, with no advantages conferred by the interventions [6, 7]; in the six-minute walking test, the GET group showed a statistically significant but clinically insignificant improvement [5]. In terms of employment, the percentage of participants in the GET group reporting lost days of work increased from 83% at baseline to 86% at 12 months after randomization; in the CBT group, the percentage was 84% both before and after treatment. In all study arms, the percentage of participants receiving unemployment or disability benefits was higher after treatment [6].

In promoting GET and CBT as effective, the PACE authors downplayed the findings on employment, receipt of disability or unemployment support, and other objective results, suggesting these should be ignored when determining whether patients had improved and recovered. In correspondence, they challenged the reliability and even the objectivity of the measures they themselves had pre-designated as objective. As they wrote: “Recovery from illness is a health status, not an economic one, and plenty of working people are unwell, while well people do not necessarily work. Some of our participants were either past the age of retirement or were not in paid employment when they fell ill. In addition, follow-up at 6 months after the end of therapy may be too short a period to affect either benefits or employment.” [16].

It is indisputable that other factors besides health status play a role in employment outcomes. Nonetheless, if the PACE trial’s reported results of significant improvement and recovery were accurate, then a measurable benefit from GET and CBT in employment and in the receipt of financial support would have been expected. As has been well-documented, the investigators weakened key subjective outcome measures in ways that dramatically improved their reported results; published re-analyses of trial data have found that no one achieved “recovery” from either of the therapies, and rates of improvement were so marginal that they were likely due to bias and expectation effects [17, 18]. Given these findings, the similarly disappointing results for employment outcomes in PACE should not be surprising.

3 Other studies on CBT/GET and employment outcomes

In a review of treatment studies that included employment outcomes, Vink and Vink-Niese [8] found that the standard interventions did not have an overall positive effect on work status. Besides PACE, among the studies reviewed were two other randomized trials and five observational studies based on data from clinical services. The two other trials, one in the Netherlands with 278 participants and one in England with 153, both investigated CBT and reported no statistically significant differences in employment outcomes between the intervention and control groups [9, 10]. The largest observational study included 952 patients seeking care at specialty clinics in England, although a great many did not provide post-treatment outcomes; among a subgroup of 394, 18% reported having returned to work or increased work hours, while 30% reported having stopped work or reduced work hours [11]. According to a Belgian report, a review of 655 patients attending domestic clinics found that “employment status decreased” when assessed after treatment while the percentage of those “living from a sickness allowance” rose from 54% to 57% [12].

Other observational research had similarly unpromising findings. In the most recent study, Stevelink et al. [13], of 508 patients who attended clinical services between 2007 and 2014, only 316 provided information about post-treatment employment status, among other measures. Of those, 9% had returned to work after not having worked at baseline. On the other hand, 6% had stopped working after having been working at baseline, leaving a net return-to-work after treatment of just 3%–a handful of people. Moreover, that figure is likely to be overstated, given the high loss-to-follow-up from the initial sample of 508. The drop-outs were more seriously ill at baseline, so they might be expected to have worse employment outcomes than those who ended up providing data at the final time point.

According to the authors, “unhelpful beliefs such as fear of activity and exercise and concerns about causing damage, combined with all or nothing behaviour and behavioural avoidance, were associated with not working” [13]. This statement is problematic because “fear of activity,” “concerns about causing damage” and related indications of caution should be considered reasonable and prudent perspectives, not “unhelpful beliefs,” among patients with the core ME/CFS symptom of PEM. Beyond that, the study itself documented little or no change after treatment in the domains of “fear-avoidance,” “catastrophizing,” “embarrassment avoidance,” “symptom focusing,” “all-or-nothing behaviour,” and “avoidance/resting behaviour,” even though such factors were “specifically targeted in CBT and, to some extent, GET.”

Moreover, the authors reported no change in subjective fatigue scores, and only a marginal increase in subjective physical function scores, with participants remaining seriously disabled even after treatment. Thus, although the authors noted correctly that “meaningful occupation is important for well-being and psychosocial needs,” their study documented that their approach failed to impact factors presumed to be essential to helping participants achieve that important goal. (Since Stevelink et al’s senior author was one of the lead PACE investigators, it is unclear why the paper did not mention the null employment results from that “definitive” study.)

The theoretical illness model underlying all of these studies is essentially the one outlined by Wessely et al. more than three decades ago [1]. That illness model is at odds with the extensive physiological abnormalities that have been found in ME/CFS [17, 19]. Research findings have also undermined two core assumptions of the model–specifically, that ME/CFS patients are deconditioned and have an unwarranted fear of activity or exercise. [20–22]. In 2017, the US Centers for Disease Control and Prevention dropped its recommendations for GET and CBT as ME/CFS treatments. In 2021, the UK National Institute for Health and Care Excellence (NICE) reversed its earlier support for the interventions in new ME/CFS guidelines; in its analysis, NICE assessed the quality of the evidence supporting GET and CBT as either “very low” or merely “low” [23]. These developments are consistent with the failure of GET and CBT to lead to improved employment outcomes in PACE and other studies.

4 Conclusion

In a recent study of employment status among clinic attendees, Stevelink et al. [13] wrote that “work-related outcomes should be targeted” in treatment for ME/CFS. It is certain that people with ME/CFS experience disrupted occupational lives and that it would be desirable to identify treatments that could restore their full capacity for employment. However, the most common behavioral and psychological interventions— that is, GET and CBT–have already been tested sufficiently to reach a conclusive assessment that they do not lead overall to meaningful improvements in work status. These poor results are consistent across randomized trials, including the high-profile and “definitive” PACE study, as well as observational studies of patients seeking clinical services for their illness.

Some investigators and medical experts continue to promote GET and CBT as treatments for ME/CFS patients based on subjective findings from flawed studies. They also seek to extend these recommendations to patients with long Covid, or PASC, many of whom are receiving ME/CFS diagnoses and facing employment challenges. It is time to state the obvious: The objective data on work outcomes indicate that GET and CBT do not lead to readily apparent benefits in this domain. In consequence, they should no longer be recommended to ME/CFS patients as a strategy for achieving occupational rehabilitation and related benefits.

Source: Tuller D, Vink M. Graded exercise therapy and cognitive behavior therapy do not improve employment outcomes in ME/CFS. Work. 2023 Mar 10. doi: 10.3233/WOR-220569. Epub ahead of print. PMID: 36911962. https://content.iospress.com/articles/work/wor220569 (Full text)

Chronic fatigue syndrome and occupational status: a retrospective longitudinal study

Dear Sir,

Occupational Medicine recently published a paper from Stevelink et al. [1] called ‘Chronic fatigue syndrome and occupational status: a retrospective longitudinal study’. Unfortunately, the paper features major technical and methodological errors that warrant urgent editorial attention.

To recap: The study started with 508 participants. The primary outcome was occupational status. Many participants had dropped out by follow-up—only 316, or 62%, provided follow-up data. Of those 316, 88% reported no change in employment status. As a group, the participants experienced either no changes or only insignificant ones in a range of secondary outcomes, including fatigue and physical function. The poor follow-up scores on fatigue and physical function alone indicate that the group remained, collectively, severely disabled after treatment.

In several sections of the paper, the authors’ description of their own statistical findings is incorrect. They make a recurring elementary error in their presentation of percentages. The authors repeatedly use the construction ‘X% of patients who did Y at baseline’ when they should have used the construction ‘X% of all 316 patients (i.e. those who provided follow-up data)’. This recurring error involving the core findings undermines the merit and integrity of the entire paper.

For example, in the Abstract, the authors state that ‘53% of patients who were working [at baseline] remained in employment [at follow-up]’. This is not accurate. Their own data (Table 2) show that 185 patients (i.e. 167 + 18) were working at baseline, and that 167 patients were working at both time points. In other words, the proportion working continuously was in fact 90% (i.e. 167 out of 185). The ‘53%’ that the authors refer to is the percentage of the sample who were employed at both time points (i.e. 167 out of 316), which is an entirely different subset. They have either misunderstood the percentage they were writing about, or they have misstated their own finding by linking it to the wrong percentage.

This error is carried over into the section on ‘Key Learning Lessons’, where the authors state that ‘Over half of the patients who were working at baseline were able to remain in work over the follow-up period…’ While 90% is certainly ‘over half’, it seems clear that this phrasing is again incorrectly referring to the 53% subset.

The same error is made with the other key findings. For example, the Abstract states that ‘Of the patients who were not working at baseline, 9% had returned to work at follow-up’. But as above, this is incorrect. A total of 131 patients (i.e. 104 + 27) were recorded as ‘not employed’ at baseline and 27 were recorded as not working at baseline but as working at follow-up. This is 21%, not 9%. Once again, the authors appear to misunderstand their own findings. The ‘9%’ they refer to is a percentage of the sample of 316; it is not, as they have it, a percentage of that subset of the sample who were initially unemployed. This erroneous ‘9%’ conclusion appears as well in the ‘Key Learning Lessons’ and in the Discussion.

And again, the authors state in the Abstract that ‘of those working at baseline, 6% were unable to continue to work at follow-up’, a claim they repeat in the section on ‘Key Learning Lessons’ and in the Discussion. This statement too is wrong. Once more, the authors mistakenly interpret a percentage of the sample of 316 as if it were a percentage of a targeted subset. In this case, they think they are referring to a percentage of patients working at baseline, but they are actually referring to a percentage of the full group that provided follow-up data.

The authors present the raw frequency data in Table 2. Readers can see for themselves how their sample of 316 patients is cross-tabulated into four subsets of interest (i.e. ‘working at baseline and follow-up’; ‘not working at baseline and follow-up’; ‘dropped out of work at follow-up’; ‘returned to work at follow-up’). From Table 2, it is clear that the prose provided in the body of the paper is at odds with the actual data.

It is undeniable that the text of this paper is replete with elementary technical errors, as described. Inevitably, the narrative is distorted by the authors’ failure to understand and correctly explain their own findings. It is unclear to us how these basic and self-evident errors were not picked up during peer review. Although we don’t know the identities of the peer reviewers, we speculate that groupthink and confirmation bias will have played their part. After all, it is generally reasonable for peer reviewers to presume that authors have understood their own computations.

There are several other features of this paper that cause concern. These include the following:

  • The authors state that they evaluated participants using guidance from the UK’s National Institute for Health and Care Excellence (NICE). (Presumably they are referring to the 2007 NICE guidance, not the revision published in October 2021.) But the reference for this statement is a 1991 paper that outlines the so-called ‘Oxford criteria’, a case definition that differs significantly from the 2007 NICE guidance. Moreover, in a paper about the same participant cohort previously published by Occupational Medicine—‘Factors associated with work status in chronic fatigue syndrome’—the authors state explicitly that these patients were diagnosed using the Oxford criteria. This inconsistency is non-trivial, because the differences between these two diagnostic approaches have substantive implications for how the findings should be interpreted. The authors’ confusion over the matter is hard to comprehend and raises fundamental questions about the validity of their research.

  • According to Table 1, there were either no changes or no meaningful changes in average scores for fatigue, physical function and multiple other secondary outcomes between the preliminary sample of 508 and the final follow-up sample of 316. The authors themselves acknowledge that the patients who dropped out before follow-up were likely to have had poorer health than those who remained. Therefore, the fact that Table 1 presents combined averages for the entire preliminary sample—i.e. combined averages for patients who dropped out and those who did not—muddies the waters. Presenting combined baseline scores for all patients will mask any declines that occurred for these variables in the subset who were followed up. It would have been far more appropriate to have isolated and presented the baseline data for the 316 followed up patients alone. Doing so would have reflected the authors’ research question more correctly, as well as enabling readers to make their own like-with-like comparisons.

  • Finally, the authors state that ‘Studies into CFS have placed little emphasis on occupational outcomes, including return to work after illness’. However, they conspicuously fail to mention the PACE trial, a high-profile large-scale British study of interventions for CFS. The PACE trial included employment status as one of four objective outcomes, with the data showing that the interventions used—the same ones as in the Occupational Medicine study—have no effect on occupational outcomes. This previous finding is so salient to the present paper that it is especially curious the authors have chosen to omit it. The omission is all the more disquieting given that the corresponding author of the paper was a lead investigator on the PACE trial itself.

Authors of research papers have an obligation to cite seminal findings from prior studies that have direct implications for the target research question. Not doing so—especially where there is overlapping authorship—falls far short of the common standards expected in scientific reporting.

Even putting these additional matters aside, the technical errors that undermine this paper’s reporting of percentages render its key conclusions meaningless. The sentences used to describe the findings are simply incorrect, and the entire thrust of the paper’s narrative is thereby contaminated. We believe that allowing the authors to publish a correction to these sentences would create only further confusion.

We therefore call on the journal to retract the paper.

Read the rest of this article HERE.

Source: Hughes BM, Tuller D. Chronic fatigue syndrome and occupational status: a retrospective longitudinal study. Occup Med (Lond). 2022 May 23;72(4):e1-e2. doi: 10.1093/occmed/kqac007. PMID: 35604311. https://academic.oup.com/occmed/article/72/4/e1/6590617?login=false (Full article)

Please Help David Tuller, Our Champion!

UPDATE: David Tuller’s fundraiser made its goal! A HUGE thank you to everyone who donated. You are helping David continue his important work on our behalf. Thank you to everybody!


David Tuller’s spring fundraiser is now live! Tuller has been tireless in his battle against the GET/CBT ideological onslaught! He has much more work to do and he needs our support.

Tuller has written more than seventy-five  posts on Vincent Racaniello’s Virology Blog, spanning ten years. His articles comprise a full history of how the PACE trial was used to mislead health care providers into thinking ME/CFS could be cured with “a walk and a talk.” Tuller has taken on some of the authors of the PACE study and, despite threats from them, has continued to challenge their findings.

In 2021, Tuller explored the intersections between the pandemic and ME, including the overlap between ME/CFS and long Covid. He kept an eye out for new bad research (CBT/GET, Lightning Process) as well as keeping an eye on goings-on at the CDC, the NIH and elsewhere.

This year, Tuller will continue in his efforts. “Because of long Covid’s range of reported symptoms, many people with the illness have medical issues unrelated to ME and will not receive an ME diagnosis. But a great many will,” he says. “So examining long Covid in the context of these scientific debates over the source and cause of the devastating symptoms is critical to sustain the momentum of change in the ME domain and affirming the advances in the ME field that have been made to date.”

Last year, Tuller successfully raised money through Crowdrise  in order to continue investigating and blogging about the PACE trial. The funds went to the School of Public Health at the University of California, Berkeley, which created a position for Tuller to continue his investigative work. Now, a year later, the funds have run out, and Tuller has to depend on the generosity of our community to continue his work.

The struggle continues! And David is fighting hard for us!

PLEASE DONATE HERE!

Please Help David Tuller, Our Champion!

David Tuller’s fundraiser is now live! Tuller has been tireless in his battle against the GET/CBT ideological onslaught! He has much more work to do and he needs our support.

Tuller has written more than seventy-five  posts on Vincent Racaniello’s Virology Blog, spanning seven years. His articles comprise a full history of how the PACE trial was used to mislead health care providers into thinking ME/CFS could be cured with “a walk and a talk.” Tuller has taken on some of the authors of the PACE study and, despite threats from them, has continued to challenge their findings.

This year, Tuller will be looking at intersections between the pandemic and ME, such as concerns about whether some COVID-19 patients will develop an ME-like disease. He will be keeping an eye out for new bad research (think: CBT and GET) and keeping an eye on goings-on at the CDC, the NIH and elsewhere.

Last year, Tuller successfully raised money through Crowdrise  in order to continue investigating and blogging about the PACE trial. The funds went to the School of Public Health at the University of California, Berkeley, which created a position for Tuller to continue his investigative work. Now, a year later, the funds have run out, and Tuller has to depend on the generosity of our community to continue his work.

PLEASE DONATE HERE!

Response to Adamson et al. (2020): ‘Cognitive behavioural therapy for chronic fatigue and chronic fatigue syndrome: Outcomes from a specialist clinic in the UK’

Abstract:

In a paper published in the Journal of the Royal Society of Medicine, Adamson et al. (2020) interpret data as showing that cognitive behavioural therapy leads to improvement in patients with chronic fatigue syndrome and chronic fatigue. Their research is undermined by several methodological limitations, including: (a) sampling ambiguity; (b) weak measurement; (c) survivor bias; (d) missing data and (e) lack of a control group. Unacknowledged sample attrition renders statements in the published Abstract misleading with regard to points of fact. That the paper was approved by peer reviewers and editors illustrates how non-rigorous editorial processes contribute to systematic publication bias.

Source: Hughes BM, Tuller D. Response to Adamson et al. (2020): ‘Cognitive behavioural therapy for chronic fatigue and chronic fatigue syndrome: Outcomes from a specialist clinic in the UK’. J Health Psychol. 2021 Apr 10:13591053211008203. doi: 10.1177/13591053211008203. Epub ahead of print. PMID: 33840241. https://pubmed.ncbi.nlm.nih.gov/33840241/

The concept of ‘illness without disease’ impedes understanding of chronic fatigue syndrome: a response to Sharpe and Greco

Abstract:

In a recent article in Medical Humanities, Sharpe and Greco characterise myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) as an ‘illness without disease’, citing the absence of identified diagnostic markers. They attribute patients’ rejection of psychological and behavioural interventions, such as cognitive–behavioural therapy (CBT) and graded exercise therapy (GET), to a ‘paradox’ resulting from a supposed failure to acknowledge that ‘there is no good objective evidence of bodily disease’. In response, we explain that understandings about the causes of and treatments for medical complaints have shifted across centuries, and that conditions once thought to be ‘psychosomatic’ have later been determined to have physiological causes.

We also note that Sharpe and Greco do not disclose that leading scientists and physicians believe that ME/CFS is a biomedical disease, and that numerous experts, not just patients, have rejected the research underlying the CBT/GET treatment approach. In conclusion, we remind investigators that medical classifications are always subject to revision based on subsequent research, and we therefore call for more humility before declaring categorically that patients are experiencing ‘illness without disease’.

Source: Lubet S, Tuller D. The concept of ‘illness without disease’ impedes understanding of chronic fatigue syndrome: a response to Sharpe and Greco [published online ahead of print, 2020 Jun 1]. Med Humanit. 2020;medhum-2019-011807. doi:10.1136/medhum-2019-011807 https://mh.bmj.com/content/early/2020/06/01/medhum-2019-011807

The ‘cognitive behavioural model’ of chronic fatigue syndrome: Critique of a flawed model

Abstract:

Chronic fatigue syndrome/myalgic encephalomyelitis is a debilitating illness that greatly impacts the lives of sufferers. A cognitive behavioural model attempts to explain illness onset and continuance with a hypothesis that the illness is perpetuated by patients’ irrational beliefs and avoidance behaviours. This theory underpins the promotion of cognitive behavioural therapy, a treatment that aims to change beliefs and behaviours. This article reports on a detailed review of the cognitive behavioural model. Our review finds that the model lacks high-quality evidential support, conflicts with accounts given by most patients and fails to account for accumulating biological evidence of pathological and physiological abnormalities found in patients. There is little scientific credibility in the claim that psycho-behavioural therapies are a primary treatment for this illness.

Source: Keith Geraghty, Leonard Jason, Madison Sunnquist, David Tuller, Charlotte Blease, Charles Adeniji. The ‘cognitive behavioural model’ of chronic fatigue syndrome: Critique of a flawed model. Health Psychology Open, Volume: 6 issue: 1,
Article first published online: April 23, 2019; Issue published: January 1, 2019. https://journals.sagepub.com/doi/10.1177/2055102919838907 (Full article)

VIDEO: David Tuller Interview | ME/CFS Alert Episode 102

David Tuller is a senior fellow in public health in journalism at the Center of Global Public Health, School of Public Health, University of California, Berkeley, CA. For a decade, Tuller was a reporter and editor at The San Francisco Chronicle. He was health editor at Salon.com. Tuller frequently writes about health for The New York Times. He covered the PACE trial results for The Times in February 2011. If you found this program helpful or informative, please consider donating to support our efforts to bring more ME/CFS related interviews to YouTube: https://www.gofundme.com/MECFSAlert

Please Help David Tuller, Our Champion!

David Tuller’s fundraiser is now live! Tuller has been tireless in his battle against the GET/CBT ideological onslaught! He has much more work to do and he needs our support.

Tuller has been touring the globe, speaking about the harm the PACE trial has caused ME/CFS patients. Recently, he co-authored a critical paper, Rethinking the treatment of chronic fatigue syndrome—a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT, that was published in BMC Psychology.

Tuller has written more than seventy-five  posts on Vincent Racaniello’s Virology Blog, spanning seven years. His articles comprise a full history of how the PACE trial was used to mislead health care providers into thinking ME/CFS could be cured with “a walk and a talk.” Tuller has taken on some of the authors of the PACE study and, despite threats from them, has continued to challenge their findings.

Last year, Tuller successfully raised money through Crowdrise  in order to continue investigating and blogging about the PACE trial. The funds went to the School of Public Health at the University of California, Berkeley, which created a position for Tuller to continue his investigative work. Now, a year later, the funds have run out, and Tuller has to depend on the generosity of our community to continue his work.

Please donate HERE!